Navigation Links
Ranbaxy Signs Agreement With Zenotech For Cancer Drugs

Pharma major Ranbaxy Laboratories Ltd today said its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc (RPI) has signed an agreement //with Hyderabad-based Zenotech Laboratories Ltd to market generic cancer drugs in the US and Canada.

Under the agreement, Zenotech Labs would develop, submit for regulatory approval and manufacture a total of 11 oncology products. Ranbaxy would market these products as generic formulations in the US and Canadian markets under the Ranbaxy label, the company said in a statement.

'We anticipate a number of additional products materialising in the days ahead as a result of this mutually beneficial partnership,' Ranbaxy's CEO and Managing Director Malvinder M Singh said.

The combined branded sales of the products that the two companies have agreed upon is estimated to be about 3.7 billion dollars.

Zenotech is a specialty generic injectables company with a biotech core and has full fledged research and development facilities in India and the US. Its oncology and biologics manufacturing facilities are located in India.

'This strategic initiative by RPI will establish our presence in the therapeutic arena by offering a basket of products in the US and Canadian markets that has breadth and depth in the management of patients diagnosed with cancer,' Ranbaxy Inc President - Corporate Development Dipak Chattraj said.

(Source:PTI News)
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Institute of Medicine Report Concludes Smoke Free Laws Prevent Heart Attacks 3B Its Time to Make All Workplaces and Public Places Smoke Free 59547 1Institute of Medicine Report Concludes Smoke Free Laws Prevent Heart Attacks 3B Its Time to Make All Workplaces and Public Places Smoke Free 59547 2Institute of Medicine Report Concludes Smoke Free Laws Prevent Heart Attacks 3B Its Time to Make All Workplaces and Public Places Smoke Free 59547 3Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 59545 1Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 59545 2Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 59545 3Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 59545 4BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 14491 1BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 14491 2BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 14491 3